Overview

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This is a multinational, open-label, single-arm trial of adjunctive SVG103 (paxalisib) treatment in adults with FCD-II, TSC, and HME.

Phase:

PHASE1

Details

Lead Sponsor:

SoVarGen Co., Ltd.